{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"15.7","upperLimit":"55.2","value":"35"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"20"}],"units":"Participants"}],"description":"Progression free survival will be defined as time from the initiation of protocol treatment to the occurrence of any of the following events: disease progression or disease recurrence or death from any cause. PFS along with the confidence intervals will be estimated using the Kaplan-Meier method.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive tazemetostat PO BID on days 1-28. Cycles repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity.","id":"OG000","title":"Treatment (Tazemetostat)"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"Up to 6 months from study entry","title":"Progression-free Survival (PFS)","type":"SECONDARY","unitOfMeasure":"percentage of participants"}